In a report released yesterday, Kristen Stewart from Barclays maintained a Buy rating on Hill-Rom (HRC), with a price target of $125.00. The company’s shares closed last Monday at $110.74, close to its 52-week high of $117.10.
According to TipRanks.com, Stewart is a 3-star analyst with an average return of 1.6% and a 61.2% success rate. Stewart covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Edwards Lifesciences.
Currently, the analyst consensus on Hill-Rom is a Strong Buy with an average price target of $127.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $117.10 and a one-year low of $72.30. Currently, Hill-Rom has an average volume of 716.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hill-Rom Holdings, Inc. is a medical technology company, which focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following business segments: Patient Support System, Front Line Care, and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility, and clinical workflow solutions. The Front Line Care segment offers respiratory care products; and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products, and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.
